Reviews/Ssris and Snris/Duloxetine reduces pain in fibromyalgia and diabetic peripheral neuropathy
· SS-CMP-03 · v2
This claim bundles two conditions together: that duloxetine eases pain both in fibromyalgia and in the nerve pain of diabetes. For fibromyalgia, the usable trials here lean in the drug's favour but the result is patchy on the main pain measures. One adult trial [3] found a clear drop on one pain scale but not on another, a teenage trial [2] narrowly missed its main target, and a combination trial [1] showed duloxetine alone was not clearly better than a dummy pill on daily pain. For the diabetic nerve-pain half, none of the usable primary trials in this corpus actually studied diabetic nerve pain at all; every number for that condition came from review papers that were set aside. Because a claim that joins two conditions is only as strong as its weaker half, and one half has no direct trial evidence here, the panel stayed cautious.
Among the primary trials that survived the study-type filter, all concern fibromyalgia. The adult trial [3] reported a significant reduction in Brief Pain Inventory average pain severity (P=0.008) but not in FIQ pain score (P=0.130). The combination trial [1] showed daily pain of 5.1 on placebo versus 4.1 on duloxetine alone, significant only for the combination versus placebo, and the adolescent trial [2] missed its primary endpoint (p=.052). Long-term [5] and open-label [6] data add favourable but uncontrolled or within-group pain signals. For diabetic peripheral neuropathy, no eligible primary trial appears; the surviving non-fibromyalgia neuropathy study [14] is oxaliplatin chemotherapy-induced neuropathy in colorectal cancer, a different population and mechanism. The contested point: The division is whether the fibromyalgia pain effect is robust: the same adult trial [3] is positive on one pain endpoint (P=0.008) and null on another (P=0.130), and monotherapy was not significant on daily pain in [1]. The deeper split is that the diabetic-neuropathy limb has no eligible primary trial, so the conjunctive claim cannot be carried by the fibromyalgia evidence alone.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is a conjunction of fibromyalgia AND diabetic peripheral neuropathy, but after the mandatory study-type filter not a single eligible primary trial addresses diabetic peripheral neuropathy — all DPN evidence (e.g. Cochrane [9] RR 1.73, NNTB 5) sits inside excluded systematic reviews. The one surviving non-FM neuropathy primary study [14] is oxaliplatin chemotherapy-induced neuropathy, a different population and mechanism. The DPN limb is therefore unsupported by eligible evidence.
The fibromyalgia pain effect repeatedly fails on primary endpoints: duloxetine monotherapy was not significant vs placebo on daily pain in [1] (only the combination was), the primary BPI endpoint missed in [2] (p=.052), and [3] was significant on BPI pain but not on FIQ pain (P=0.130). The pain reduction is modest and endpoint-dependent, not robust.
Where it remains uncertain. The same trial [3] was not significant on FIQ pain (P=0.130), monotherapy was not significant on daily pain in [1], the adolescent trial [2] missed its endpoint (p=.052), and every diabetic-neuropathy number sits inside excluded reviews.
Aleatory
The strongest placebo-controlled fibromyalgia pain signal [1] rests on only 41 randomized participants in a crossover design, leaving the daily-pain estimate (4.1 vs 5.1 placebo) vulnerable to chance.
Epistemic
Every diabetic-peripheral-neuropathy number lives in excluded reviews ([9] RR 1.73, NNTB 5), so the corpus holds no eligible primary trial to establish the diabetic-neuropathy limb.
Inferential
The only surviving non-FM neuropathy primary study [14] is oxaliplatin chemotherapy-induced neuropathy in colorectal cancer, a different mechanism and population that cannot be extrapolated to diabetic neuropathy.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Duloxetine monotherapy lowered daily pain numerically but not significantly vs placebo in this FM crossover (N=41).
“Daily pain during placebo, pregabalin, duloxetine, and combination was 5.1, 5.0, 4.1, and 3.7, respectively (P < 0.05 only for combination vs placebo, and pregabalin).”
Panel auditInternal validity: medium · scope of inference: Adults with fibromyalgia; duloxetine monotherapy daily pain versus placebo over 6 weeks.Key limitations: small sample · duloxetine-vs-placebo pain not flagged significant · crossover design · trial focused on combination therapy
Juvenile FM trial missed its primary pain endpoint, though responder analyses favoured duloxetine.
“the mean change was not statistically different between duloxetine and placebo (- 1.62 vs. -0.97, respectively; p = .052)”
Panel auditInternal validity: high · scope of inference: Adolescents aged 13-17 with juvenile fibromyalgia; 24-h average pain severity at week 13.Key limitations: primary endpoint missed (p = .052) · adolescent-only population · mixed primary vs responder findings
Strongest eligible FM result: significant placebo-controlled reduction in average pain severity in adults (N=207).
“but not significantly more on the FIQ pain score (P = 0.130)”
Panel auditInternal validity: high · scope of inference: Adults with primary fibromyalgia (89% female); pain over 12 weeks, effect largely in women.Key limitations: co-primary FIQ pain not significant · benefit concentrated in women · possible mental-symptom mediation
Both arms received duloxetine and pain improved over time in both, with no placebo/no-drug comparator, so the abstract cannot isolate duloxetine's effect on pain.
Panel auditInternal validity: low · scope of inference: Adults with fibromyalgia already on duloxetine; incremental effect of adding exercise, not duloxetine's own pain effect.Key limitations: no drug-free control · both arms on duloxetine · short duration · small sample
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A conjunctive claim whose fibromyalgia limb is modestly and inconsistently supported and whose diabetic-neuropathy limb has no eligible primary evidence cannot exceed Uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Eligible primary diabetic-peripheral-neuropathy trial. The diabetic-neuropathy limb of this conjunctive claim has no eligible primary evidence in the corpus; it rests on excluded reviews only. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled randomized trial of duloxetine in diabetic peripheral neuropathy with a pre-specified pain primary endpoint, carried as primary evidence.
Open question: Does duloxetine reduce pain in diabetic peripheral neuropathy when tested as eligible primary evidence rather than within reviews? Why it is still open: Every diabetic-neuropathy figure in the corpus ([9] RR 1.73, NNTB 5) sits inside excluded systematic reviews; no primary diabetic-neuropathy trial survived the study-type filter.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19